


Angiotensin Receptor

HDAC Inhibitor:
Vorinostat (SAHA)





HDAC (Histone deacetylase)


Angiotensin receptors are a class of G protein-coupled receptors with angiotensin II as their ligands. They are important in the renin-angiotensin system: they are responsible for the signal transduction of the vasoconstricting stimulus of the main effector hormone, angiotensin II. The AT1 and AT2 receptors have a similar affinity for angiotensin II, which is their main ligand. The AT1 receptor is the best elucidated angiotensin receptor. AT2 receptors are more plentiful in the fetus and neonate. Other poorly characterized subtypes include the AT3 and AT4 receptors.


Angiotensin Receptor Inhibitors & Modulators


<p>A 779</p> <p style="text-align: right;">Cat. No.: HY-P0216</p>	<p>A81988 (Abbott81988)</p> <p style="text-align: right;">Cat. No.: HY-U00188</p>
<p>Bioactivity: A 779 is a specific antagonist of G-protein coupled receptor (Mas receptor), which is an Ang1-7 receptor distinct from the classical AngII.</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in Water, 1 mg, 5 mg</p> 	<p>Bioactivity: A81988 is a potent, competitive, non-peptidic antagonist of angiotensin AT₁ receptors.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg, 10 mg, 20 mg</p> 
<p>Angiotensin 1-7 (Angiotensin-(1-7); Ang-(1-7))</p> <p style="text-align: right;">Cat. No.: HY-12403</p>	<p>Angiotensin II (1-4), human</p> <p style="text-align: right;">Cat. No.: HY-P1792</p>
<p>Bioactivity: Angiotensin (1-7) inhibits purified canine angiotensin converting enzyme (ACE) activity with an IC₅₀ of 0.65 μM.</p> <p>Purity: 99.61%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg, 50 mg</p> 	<p>Bioactivity: Angiotensin II (1-4), human is an endogenous peptide produced from AT I by angiotensin-converting-enzyme (ACE). Angiotensin II binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells and increasing intracellular Ca²⁺ levels. Angiotensin II also acts at the Na⁺/H⁺ ...</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size:</p> 
<p>Angiotensin II (3-8), human</p> <p style="text-align: right;">Cat. No.: HY-P1515</p>	<p>Angiotensin II (3-8), human TFA</p> <p style="text-align: right;">Cat. No.: HY-P1515A</p>
<p>Bioactivity: Angiotensin II (3-8), human is a less effective agonist at the angiotensin AT₁ receptor.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg</p> 	<p>Bioactivity: Angiotensin II (3-8), human (TFA) is a less effective agonist at the angiotensin AT₁ receptor.</p> <p>Purity: 98.99%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg</p> 
<p>Angiotensin II (5-8), human</p> <p style="text-align: right;">Cat. No.: HY-P1769</p>	<p>Angiotensin II 5-valine (Valine angiotensin II; 5-L-Valine angiotensin II)</p> <p style="text-align: right;">Cat. No.: HY-P0108</p>
<p>Bioactivity: Angiotensin II (5-8), human is an endogenous C-terminal fragment of the peptide vasoconstrictor angiotensin II ^[1]. Angiotensin II binds the AT II type 1 (AT1) receptor, stimulating GPCRs in vascular smooth muscle cells ...</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size:</p> 	<p>Bioactivity: Angiotensin II 5-valine is an agonist of angiotensin receptor.</p> <p>Purity: 95.90%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg</p> 
<p>Angiotensin II human (Angiotensin II; Hypertension II; Ang II; DRVYIHPF)</p> <p style="text-align: right;">Cat. No.: HY-13948</p>	<p>Angiotensin III</p> <p style="text-align: right;">Cat. No.: HY-113035</p>
<p>Bioactivity: Angiotensin II human is a vasoconstrictor that acts on the AT1 and the AT2 receptor.</p> <p>Purity: 99.96%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10 mg, 50 mg</p> 	<p>Bioactivity: Angiotensin III is an angiotensin 1 (AT1) and AT2 receptor agonist.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg</p> <p style="text-align: right;">Angiotensin III</p> 


Angiotensin III TFA	Cat. No.: HY-113035A
Bioactivity: Angiotensin III (TFA) is an angiotensin 1 (AT1) and AT2 receptor agonist.	
Purity: >98%	
Clinical Data: No Development Reported	
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg	


Angiotensin III, human, mouse	Cat. No.: HY-P1540
Bioactivity: Angiotensin III, human, mouse is a heptapeptide, acts as an endogenous angiotensin type 2 receptor (AT₂R) agonist, with IC₅₀s of 0.648 nM and 21.1 nM for AT ₂ R and AT ₁ R, respectively.	
Purity: >98%	
Clinical Data: No Development Reported	
Size: 5 mg, 10 mg, 25 mg	


AVE 0991	Cat. No.: HY-15778
Bioactivity: AVE 0991 is a nonpeptide and orally active angiotensin-(1-7) receptor agonist with an IC₅₀ of 21 nM.	
Purity: 99.92%	
Clinical Data: No Development Reported	
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	


AVE 0991 sodium salt	Cat. No.: HY-15778A
Bioactivity: AVE 0991 sodium salt is a nonpeptide and orally active Ang-(1-7) receptor Mas agonist. AVE 0991 competes for high-affinity binding of [¹²⁵ I]-Ang-(1-7) to bovine aortic endothelial cell membranes with IC₅₀ of 21±35 nM.	
Purity: 99.32%	
Clinical Data: No Development Reported	
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	


Azilsartan (TAK-536)	Cat. No.: HY-14914
Bioactivity: Azilsartan(TAK-536) is a specific and potent angiotensin II type 1 receptor antagonist with IC50 of 2.6 nM.	
Purity: 99.58%	
Clinical Data: Launched	
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg	









Azilsartan D5 (TAK-536 D5)	Cat. No.: HY-14914S
Bioactivity: Azilsartan D5 is the deuterium labeled Azilsartan(TAK-536), which is a specific and potent angiotensin II type 1 receptor antagonist.	
Purity: 98.0%	
Clinical Data: No Development Reported	
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg	

Azilsartan medoxomil (TAK-491)	Cat. No.: HY-14736
Bioactivity: Azilsartan medoxomil(TAK 491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.	
Purity: >98%	
Clinical Data: Launched	
Size: 5 mg, 10 mg, 50 mg	

Azilsartan medoxomil monopotassium (Azilsartan kamedoxomil; TAK 491 monopotassium)	Cat. No.: HY-17458
Bioactivity: Azilsartan medoxomil(TAK 491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.	
Purity: 95.35%	
Clinical Data: Launched	
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg	



BIBS 39	Cat. No.: HY-19732
Bioactivity: BIBS 39 is a new nonpeptide angiotensin II (AII) receptor antagonist.	
Purity: 99.70%	
Clinical Data: No Development Reported	
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg	

C-Type Natriuretic Peptide (1-53), human	Cat. No.: HY-P1815
Bioactivity: C-Type Natriuretic Peptide (1-53), human is the 1-53 fragment of C-Type Natriuretic Peptide. C-Type Natriuretic Peptide is natriuretic peptide family peptide that is involved in the maintenance of electrolyte-fluid balance and vascular tone [1].	
Purity: >98%	
Clinical Data: No Development Reported	
Size:	

<p>C-Type Natriuretic Peptide (CNP) (1-22), human Cat. No.: HY-P1237</p>	<p>Candesartan (CV 11974) Cat. No.: HY-B0205</p>
<p>Bioactivity: C-Type Natriuretic Peptide (CNP) (1-22), human is the 1-22 fragment of C-Type Natriuretic Peptide. C-type natriuretic peptide is natriuretic peptide family peptide that is involved in the maintenance of electrolyte-fluid balance and vascular tone.</p> <p>Purity: 96.25%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in Water, 500u g, 1 mg, 5 mg</p>	<p>Bioactivity: Candesartan is an angiotensin II receptor antagonist with IC50 of 0.26 nM.</p> <p>Purity: 98.34%</p> <p>Clinical Data: Launched</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg</p> 
<p>Candesartan Cilexetil (TCV-116) Cat. No.: HY-17505</p>	<p>Candesartan D4 (CV-11974 D4) Cat. No.: HY-B0205S</p>
<p>Bioactivity: Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.</p> <p>Purity: 98.0%</p> <p>Clinical Data: Launched</p> <p>Size: 10mM x 1mL in DMSO, 500 mg, 1 g</p> 	<p>Bioactivity: Candesartan D4 is the deuterium labeled Candesartan, which is an angiotensin II receptor antagonist.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg, 10 mg</p> 
<p>CGP-42112 (CGP42112A) Cat. No.: HY-12405</p>	<p>CGP48369 Cat. No.: HY-101706</p>
<p>Bioactivity: CGP-42112(CGP-42112A) is a potent Angiotensin-II subtype 2 receptor(AT2 R) agonist. IC50 value: Target: AT2 R agonist in vitro: CGP42112 (>=1 nM) significantly inhibited cGMP production from the basal value. CGP42112 (>=1 nM) significantly inhibited TH-enzyme activity from the basal...</p> <p>Purity: 98.82%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in DMSO, 1 mg, 5 mg</p> 	<p>Bioactivity: CGP48369 is a nonpeptidic angiotensin II receptor antagonist, used for anti-hypertensive research.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg, 10 mg, 20 mg</p> 
<p>Elisartan (HN 65021) Cat. No.: HY-19214</p>	<p>Eprosartan mesylate (SKF-108566J) Cat. No.: HY-15834A</p>
<p>Bioactivity: Elisartan is an orally active non-peptide pro-drug of angiotensin II AT1 receptor antagonist HN-12206, and shows anti-hypertension activities.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg, 10 mg, 20 mg</p> 	<p>Bioactivity: Eprosartan is a nonpeptide angiotensin II receptor antagonist with IC50 of 9.2 and 3.9 nM in rat and human adrenal cortical membranes, respectively.</p> <p>Purity: 99.94%</p> <p>Clinical Data: Launched</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</p> 
<p>Fimasartan (BR-A-657) Cat. No.: HY-B0780</p>	<p>H-Val-Pro-Pro-OH Cat. No.: HY-114161</p>
<p>Bioactivity: Fimasartan(BR-A-657) is a non-peptide angiotensin II receptor antagonist used for the treatment of hypertension and heart failure.</p> <p>Purity: 98.77%</p> <p>Clinical Data: Launched</p> <p>Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</p> 	<p>Bioactivity: H-Val-Pro-Pro-OH, a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme (ACE), with an IC₅₀ of 9 μM.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 5 mg, 10 mg, 25 mg</p> 

<p>H-Val-Pro-Pro-OH TFA</p> <p style="text-align: right;">Cat. No.: HY-114161A</p>	<p>Irbesartan (SR-47436; BMS-186295)</p> <p style="text-align: right;">Cat. No.: HY-B0202</p>
<p>Bioactivity: H-Val-Pro-Pro-OH (TFA), a milk-derived proline peptides derivative, is an inhibitor of Angiotensin I converting enzyme (ACE), with an IC_{50} of 9 μM.</p> <p>Purity: 98.0%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 10mM x 1mL in Water, 5 mg, 10 mg, 25 mg, 50 mg</p> 	<p>Bioactivity: Irbesartan is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist with IC_{50} of 1.3 nM.</p> <p>Purity: 99.79%</p> <p>Clinical Data: Launched</p> <p>Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg</p> 
<p>Irbesartan D4 (SR-47436 D4; BMS-186295 D4)</p> <p style="text-align: right;">Cat. No.: HY-B0202S</p>	<p>L-159282 (MK 996)</p> <p style="text-align: right;">Cat. No.: HY-19191</p>
<p>Bioactivity: Irbesartan D4 is the deuterium labeled Irbesartan, which is a highly potent and specific angiotensin II type 1 (AT1) receptor antagonist.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p> 	<p>Bioactivity: L-159282 is a highly potent, orally active, nonpeptide angiotensin II receptor antagonist, with anti-hypertensive activity.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg, 10 mg, 20 mg</p> 
<p>L162389</p> <p style="text-align: right;">Cat. No.: HY-101618</p>	<p>L162441</p> <p style="text-align: right;">Cat. No.: HY-U00245</p>
<p>Bioactivity: L162389 is a potent antagonist of angiotensin AT1 receptor with K_i of 28 nM.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg, 10 mg, 20 mg</p> 	<p>Bioactivity: L162441 is an Angiotensin type 1 receptor antagonist.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg, 10 mg, 20 mg</p> 
<p>LCZ696 (Sacubitril mixture with Valsartan)</p> <p style="text-align: right;">Cat. No.: HY-18204A</p>	<p>Losartan (DuP-753)</p> <p style="text-align: right;">Cat. No.: HY-17512</p>
<p>Bioactivity: LCZ696 is a dual angiotensin II receptor and neprilysin inhibitor.</p> <p>Purity: 99.99%</p> <p>Clinical Data: Launched</p> <p>Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg</p> 	<p>Bioactivity: Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC_{50} of 20 nM.</p> <p>Purity: 99.24%</p> <p>Clinical Data: Launched</p> <p>Size: 10mM x 1mL in DMSO, 1 g, 5 g</p> 
<p>Losartan D4 (DuP-753 D4)</p> <p style="text-align: right;">Cat. No.: HY-17512S</p>	<p>Losartan D4 Carboxylic Acid (E-3174 D4; EXP-3174 D4)</p> <p style="text-align: right;">Cat. No.: HY-12765S</p>
<p>Bioactivity: Losartan D4 is the deuterium labeled Losartan. Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC_{50} of 20 nM.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg</p> 	<p>Bioactivity: Losartan D4 Carboxylic Acid is the deuterium labeled Losartan(EXP-3174), which is an angiotensin II receptor antagonist.</p> <p>Purity: >98%</p> <p>Clinical Data: No Development Reported</p> <p>Size: 1 mg, 5 mg, 10 mg</p> 

<p>Losartan potassium (DuP-753 potassium) Cat. No.: HY-17512A</p>	<p>LY285434 Cat. No.: HY-U00202</p>
<p>Bioactivity: Losartan (potassium) is an angiotensin II receptor type 1 (AT1) antagonist, competing with the binding of angiotensin II to AT1 with an IC₅₀ of 20 nM.</p> <p>Purity: 99.91% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 1 g, 5 g</p> 	<p>Bioactivity: LY285434 is a suitable angiotensin II receptor antagonist.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 20 mg</p> 
<p>Olmesartan (RNH 6270; CS 088) Cat. No.: HY-17004</p>	<p>Olmesartan D4 (RNH-6270 D4; CS-088 D4) Cat. No.: HY-17004S</p>
<p>Bioactivity: Olmesartan is an angiotensin II receptor (AT1R) antagonist used to treat high blood pressure.</p> <p>Purity: 99.01% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 100 mg, 500 mg</p> 	<p>Bioactivity: Olmesartan D4 is the deuterium labeled Olmesartan. Olmesartan is an angiotensin II receptor (AT1R) antagonist used to treat high blood pressure.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 
<p>Olmesartan medoxomil (CS 866) Cat. No.: HY-17005</p>	<p>Olodanrigan (EMA401; PD-126055) Cat. No.: HY-13106</p>
<p>Bioactivity: Olmesartan medoxomil is a potent and selective angiotensin AT1 receptor inhibitor with IC₅₀ of 66.2 μM.</p> <p>Purity: 99.03% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</p> 	<p>Bioactivity: Olodanrigan (EMA401), a highly selective AT2R antagonist, inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons.</p> <p>Purity: 99.29% Clinical Data: Phase 2 Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg</p> 
<p>PD 123319 (S)-(+)-PD 123319) Cat. No.: HY-10259</p>	<p>PD 123319 ditrifluoroacetate Cat. No.: HY-10259A</p>
<p>Bioactivity: PD 123319 (ditrifluoroacetate) is a potent, selective AT2 angiotensin II receptor antagonist with IC₅₀ of 34 nM.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 5 mg, 10 mg, 50 mg</p> 	<p>Bioactivity: PD 123319 (ditrifluoroacetate) is a potent, selective AT2 angiotensin II receptor antagonist with IC₅₀ of 34 nM.</p> <p>Purity: 99.76% Clinical Data: No Development Reported Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg</p> 
<p>Prasartan (FW 7203; KD 3-671; KT 3671) Cat. No.: HY-101574</p>	<p>SL910102 Cat. No.: HY-100292</p>
<p>Bioactivity: Prasartan is a selective angiotensin II receptor antagonist.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg, 20 mg</p> 	<p>Bioactivity: SL910102 is a nonpeptide angiotensin AT₁ receptor antagonist.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg, 10 mg</p> 

<p>Sparsentan (RE-021; DARA-a) Cat. No.: HY-17621</p> <p>Bioactivity: Sparsentan (RE-021; BMS-346567; PS433540; DARA-a) is a highly potent dual angiotensin II and endothelin A receptor antagonist with K_is of 0.8 and 9.3 nM, respectively.</p> <p>Purity: 99.08% Clinical Data: Phase 2 Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</p> 	<p>Tasosartan (WAY-ANA 756) Cat. No.: HY-A0250</p> <p>Bioactivity: Tasosartan is a long-acting angiotensin II (AngII) receptor antagonist.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 5 mg, 10 mg</p> 
<p>TD-0212 Cat. No.: HY-114412</p> <p>Bioactivity: TD-0212 (compound 35) is an orally active dual pharmacology angiotensin II type 1 receptor (AT₁) antagonist and nephrilysin (NEP) inhibitor, with a pK_i of 8.9 for AT₁ and a pIC_{50} of 9.2 for NEP [1].</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 500 mg, 100 mg, 250 mg</p> 	<p>Telmisartan (BIBR 277) Cat. No.: HY-13955</p> <p>Bioactivity: Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT₁), selectively inhibiting the binding of ¹²⁵I-AngII to AT₁ receptors with IC_{50} of 9.2 nM.</p> <p>Purity: 99.96% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 50 mg, 100 mg, 500 mg, 1 g</p> 
<p>Tranilast (MK 341; SB 252218) Cat. No.: HY-B0195</p> <p>Bioactivity: Tranilast is an antiallergic agent. Target: Angiotensin Receptor Tranilast has been approved in Japan and South Korea, since 1982, for the treatment of bronchial asthma, with indications for keloids and hypertrophic scar added in 1993. Tranilast is also used to treat asthma, autoimmune diseases,...</p> <p>Purity: 99.60% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 10 mg, 50 mg</p> 	<p>Tranilast Sodium (Sodium Tranilast; MK 341 Sodium; SB 252218 Sodium) Cat. No.: HY-B0195A</p> <p>Bioactivity: Tranilast is an antiallergic agent. Target: Angiotensin Receptor Tranilast has been approved in Japan and South Korea, since 1982, for the treatment of bronchial asthma, with indications for keloids and hypertrophic scar added in 1993. Tranilast is also used to treat asthma, autoimmune diseases,...</p> <p>Purity: >98% Clinical Data: Launched Size: 10 mg, 50 mg</p> 
<p>Tranilast trans- (trans-Tranilast) Cat. No.: HY-18706</p> <p>Bioactivity: Trans-Tranilast is an antiallergic drug, used to treat bronchial asthma, allergic rhinitis and atopic dermatitis.</p> <p>Purity: 99.66% Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, 10 mg, 50 mg</p> 	<p>Valsartan (CGP 48933) Cat. No.: HY-18204</p> <p>Bioactivity: Valsartan (CGP-48933) is an angiotensin II receptor antagonist for the treatment of high blood pressure and heart failure.</p> <p>Purity: 99.35% Clinical Data: Launched Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</p> 
<p>Valsartan D9 (CGP-48933 D9) Cat. No.: HY-18204S</p> <p>Bioactivity: Valsartan D9 (CGP-48933 D9) is deuterium labeled valsartan. Valsartan is an angiotensin II receptor antagonist for treatment of high blood pressure and heart failure.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p> 	<p>ZD 7155(hydrochloride) Cat. No.: HY-102093</p> <p>Bioactivity: ZD 7155 hydrochloride is an angiotensin II receptor type 1 (AT₁ receptor) antagonist.</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 250 mg, 500 mg</p> 

[Sar1, Ile8]-Angiotensin II

Cat. No.: HY-P1564

Bioactivity: [Sar1, Ile8]-Angiotensin II is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels.

Purity: >98%

Clinical Data: No Development Reported

Size: 10 mg, 50 mg

